cells
nobeastsofierce / shutterstock.com
22 December 2016Big PharmaGlyn Truscott

The challenges of patenting cell therapies

The use of living cells as therapeutic agents is a revolutionary step forward, often said to be the next major development in human medicine. Cell therapies present unique therapeutic opportunities and differ significantly from conventional small molecule therapies, and also more complex biologics, in many respects: in development, production, mechanism of action, regulation, and in some cases even the ability to be copied.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
1 July 2026   Otsuka v Sun Pharma could redefine which pharmaceutical patents qualify for patent term extensions, with major implications for innovator companies, generic manufacturers and the future of market exclusivity in the country.
Big Pharma
18 June 2026   Despite a slowdown in US patent litigation, life sciences remains one of the most active sectors—but companies are using a wider than ever IP toolkit, says a new study.
Big Pharma
15 April 2026   The Danish pharma giant is turning to artificial intelligence as it faces patent expiry, falling shares and intensifying competition from Eli Lilly.